CRISPR THERAPEUTICS AG (CRSP)
55.79USD
-1.24% (-0.70)
Over 1M:
+4.2%
7 Aug
12 Aug
17 Aug
20 Aug
25 Aug
28 Aug
2 Sep
Q3 '21 — Revenue: 824K
Q3 '21 — Operating Income: -128.8M
Q3 '21 — Operating Cash Flow: -81.3M
Q3 '21 — Free Cash Flow: -118.4M
Q3 '21 — Net Income: -127.2M
Q4 '21 — Revenue: 12.9M
Q4 '21 — Operating Income: -145.7M
Q4 '21 — Operating Cash Flow: -86M
Q4 '21 — Free Cash Flow: -95.2M
Q4 '21 — Net Income: -141.2M
Q1 '22 — Revenue: 940K
Q1 '22 — Operating Income: -176M
Q1 '22 — Operating Cash Flow: -135.2M
Q1 '22 — Free Cash Flow: -150.6M
Q1 '22 — Net Income: -179.2M
Q2 '22 — Revenue: 158K
Q2 '22 — Operating Income: -183.3M
Q2 '22 — Operating Cash Flow: -142M
Q2 '22 — Free Cash Flow: -151.6M
Q2 '22 — Net Income: -185.8M
Q3 '22 — Revenue: 94K
Q3 '22 — Operating Income: -182.4M
Q3 '22 — Operating Cash Flow: -105.2M
Q3 '22 — Free Cash Flow: -111.2M
Q3 '22 — Net Income: -174.5M
Q4 '22 — Revenue: 6K
Q4 '22 — Operating Income: -131.5M
Q4 '22 — Operating Cash Flow: -113.3M
Q4 '22 — Free Cash Flow: -119.5M
Q4 '22 — Net Income: -110.6M
Q1 '23 — Revenue: 100M
Q1 '23 — Operating Income: -64.5M
Q1 '23 — Operating Cash Flow: 8.8M
Q1 '23 — Free Cash Flow: 5.7M
Q1 '23 — Net Income: -53.1M
Q2 '23 — Revenue: 70M
Q2 '23 — Operating Income: -95.2M
Q2 '23 — Operating Cash Flow: -133.2M
Q2 '23 — Free Cash Flow: -136.8M
Q2 '23 — Net Income: -77.7M
Q3 '23 — Revenue: 0
Q3 '23 — Operating Income: -132.4M
Q3 '23 — Operating Cash Flow: -39.9M
Q3 '23 — Free Cash Flow: -42M
Q3 '23 — Net Income: -112.2M
Q4 '23 — Revenue: 201.2M
Q4 '23 — Operating Income: 69.6M
Q4 '23 — Operating Cash Flow: -96.1M
Q4 '23 — Free Cash Flow: -96.8M
Q4 '23 — Net Income: 89.3M
Q1 '24 — Revenue: 504K
Q1 '24 — Operating Income: -140.6M
Q1 '24 — Operating Cash Flow: 109.8M
Q1 '24 — Free Cash Flow: 109M
Q1 '24 — Net Income: -116.6M
Q2 '24 — Revenue: 517K
Q2 '24 — Operating Income: -151.3M
Q2 '24 — Operating Cash Flow: -95.6M
Q2 '24 — Free Cash Flow: -96.3M
Q2 '24 — Net Income: -126.4M
Q3 '24 — Revenue: 602K
Q3 '24 — Operating Income: -110.1M
Q3 '24 — Operating Cash Flow: -106.9M
Q3 '24 — Free Cash Flow: -107.1M
Q3 '24 — Net Income: -85.9M
Q4 '24 — Revenue: 35.7M
Q4 '24 — Operating Income: -64.6M
Q4 '24 — Operating Cash Flow: -50M
Q4 '24 — Free Cash Flow: -50.3M
Q4 '24 — Net Income: -37.3M
Q1 '25 — Revenue: 865K
Q1 '25 — Operating Income: -148.4M
Q1 '25 — Operating Cash Flow: -53.9M
Q1 '25 — Free Cash Flow: -54.2M
Q1 '25 — Net Income: -136M
Q2 '25 — Revenue: 892K
Q2 '25 — Operating Income: -229.3M
Q2 '25 — Operating Cash Flow: -113.9M
Q2 '25 — Free Cash Flow: -114M
Q2 '25 — Net Income: -208.5M
Q3 '25 — Revenue: 889K
Q3 '25 — Operating Income: -132.1M
Q3 '25 — Operating Cash Flow: -84.6M
Q3 '25 — Free Cash Flow: -84.7M
Q3 '25 — Net Income: -106.4M
Q4 '25 — Revenue: 864K
Q4 '25 — Operating Income: -154.8M
Q4 '25 — Operating Cash Flow: -92.6M
Q4 '25 — Free Cash Flow: -93.1M
Q4 '25 — Net Income: -130.6M
Q1 '26 — Revenue: 1.5M
Q1 '26 — Operating Income: -130.2M
Q1 '26 — Operating Cash Flow: -108.9M
Q1 '26 — Free Cash Flow: -109.4M
Q1 '26 — Net Income: -122.9M
Q2 '26 — Revenue: 10.2M
Q2 '26 — Operating Income: -117.3M
Q2 '26 — Operating Cash Flow: -83.5M
Q2 '26 — Free Cash Flow: -84.1M
Q2 '26 — Net Income: -91.2M
-180M
-90M
0
90M
180M
270M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Revenue
Operating Income
Operating Cash Flow
Free Cash Flow
Net Income
5-year valuation
1255 trading days
Price to Earnings
64th pct
15.6×
0th 10.7×
25th 13.0×
50th 14.4×
75th 16.7×
100th 22.4×
Price to Sales
87th pct
402.1×
0th 3.6×
25th 17.3×
50th 38.7×
75th 208.5×
100th 1606.0×
Price to Operating Cash Flow
47th pct
9.6×
0th 6.6×
25th 8.8×
50th 9.8×
75th 11.9×
100th 18.2×
Price to Free Cash Flow
50th pct
11.7×
0th 8.0×
25th 10.4×
50th 11.8×
75th 14.0×
100th 19.9×
Price to Book
91st pct
3.1×
0th 1.5×
25th 2.0×
50th 2.3×
75th 2.7×
100th 3.8×
EV / EBITDA
64th pct
12.5×
0th 7.9×
25th 10.1×
50th 11.5×
75th 13.6×
100th 18.2×
How it scores
For a valuation multiple, the low end is the good end.
How much of the revenue is really kept — and what did it take to earn it?
1.0
What does the price ask for what the company earns, owns and pays out?
0.8
How predictable is the revenue, and how much of it is already committed?
4.5
Can the balance sheet absorb a bad year?
6.8
Is the business getting bigger, and is it getting more profitable?
4.7
A measure absent from a block could not be computed from this company's
filings. It is left out rather than scored as though it were bad, and the dimension is
averaged over what remains. A score is measured against a fixed scale this model states;
the bar is measured against the other companies, so the two can disagree — and where
they do, that disagreement is the more interesting figure.
This is not investment advice.
Stock Scorer is a tool for reading filings, not a recommendation to buy, sell or hold anything. Nobody here is a licensed adviser, no part of this is a personal recommendation, and none of it takes account of your circumstances, your other holdings or what you can afford to lose.
Every figure comes from SEC filings and public prices, which can be late, restated or wrong; the model can read a tag incorrectly, and it says nothing about competition, management, regulation, litigation or anything else that is not a tagged number. A high total means the filings look good on the measures chosen here, which is a starting point for reading the annual report — not a substitute for doing so. Prices are delayed. Past figures do not predict future ones. Any decision you make from this is yours alone, and the authors accept no liability for it.
Browse all 61 measures
· See who ranks highest on each measure
· Browse every company scored
Terms of use
— what this is, what it is not, and what nobody here is liable for.
What this site stores about you
— every field, how long it is kept, and who else ever sees it.